Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Acquires Australia’s Southern Cross

Builds Up Position In Australia By Adding Portfolio Worth Over $22m

Executive Summary

Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.

You may also be interested in...



GBMA Welcomes Australian Investment

Australia’s GBMA off-patent industry association has welcomed the announcement of significant healthcare investment in the country’s federal budget.

Australia Extends Biosimilar Education Efforts

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

Australia Plans Accelerated Approvals

Australia’s Therapeutic Goods Administration has proposed a range of mechanisms to reduce regulatory burden on companies with the explicit aim of addressing medicines shortages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel